Pfizer Rated Among 14 Best Affordable Dividend Stocks by Analysts
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy PFE?
Source: Yahoo Finance
- Downgrade Initiation: On February 25, RBC Capital initiated coverage of Pfizer (PFE) with an Underperform rating and a $25 price target, forecasting a significant revenue decline of $15 billion to $20 billion by 2030, indicating limited visibility into new products that could mitigate losses and potentially pressuring the stock price.
- Dividend Support: Although Pfizer's dividend yield stands at approximately 6%, above the peer average, analysts caution that this may not be sufficient to offset the deeper structural challenges the company faces, especially in the absence of meaningful catalysts heading into 2026.
- Expansion in China: Pfizer signed a licensing agreement with China-based Sciwind Biosciences for its type 2 diabetes drug ecnoglutide, which could yield up to $495 million in milestone payments for Sciwind, further supporting Pfizer's expansion in China's metabolic disease market.
- Competitive Landscape: Despite ecnoglutide receiving approval in China, Pfizer did not disclose the upfront payment amount, launch timing, or expected pricing, and notably, the drug will not be covered under China's national health insurance program, highlighting competitive pressures in the rapidly growing GLP-1 drug market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.100
Low
24.00
Averages
28.56
High
35.00
Current: 27.100
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's BRAFTOVI Receives Full FDA Approval
- FDA Full Approval: Pfizer's BRAFTOVI combination regimen has received full FDA approval for adult patients with metastatic colorectal cancer harboring the BRAF V600E mutation, based on significant survival improvements from the Phase 3 BREAKWATER trial, which is expected to enhance Pfizer's market presence in oncology.
- Positive Market Reaction: Following the FDA approval announcement, Pfizer's shares rose 0.02% to $27.14, reflecting a favorable market response, while the broader market also gained 0.53%, indicating a positive overall market environment.
- Technical Analysis Shows Short-term Pressure: Currently, Pfizer's stock is trading 3.1% below its 20-day and 5.4% below its 100-day simple moving averages, indicating some selling pressure in the short term, despite a 29% increase in share price over the past 12 months.
- Analyst Ratings Remain Neutral: The average price target for Pfizer's stock is $29.42, with analysts generally maintaining a Hold rating; Barclays has downgraded its rating to Underweight with a target of $25.00, reflecting a cautious outlook on Pfizer's future performance.
See More
ViiV Healthcare Unveils Phase 1 Data for VH184 and VH499 Long-Acting HIV Treatments
- VH184 Potential: VH184, the first third-generation integrase inhibitor, shows potential for twice-yearly dosing, with a single injection maintaining drug levels for up to six months, which could significantly reduce medication frequency for HIV patients and enhance their quality of life.
- Resistance Advantage: In vitro studies indicate that VH184 exhibits improved potency and resistance characteristics compared to bictegravir, retaining activity against various resistant HIV strains, highlighting its importance and competitive potential in future HIV treatments.
- VH499 Tolerability: VH499, an investigational capsid inhibitor, demonstrates good tolerability in clinical trials, supporting ultra-long-acting dosing every six months, potentially providing more treatment options for HIV patients and further driving ViiV's innovation in HIV care.
- R&D Commitment: ViiV Healthcare is committed to advancing innovative long-acting HIV therapies, with early data on VH184 and VH499 showcasing the company's efforts to reduce daily treatment needs, aligning with patient demands for more flexible treatment options and potentially transforming the future of HIV care.
See More
Astellas Reports Consistent Safety Profile for Perioperative Enfortumab Vedotin and Pembrolizumab in EV-304 Study
Safety Profile Overview: The document outlines the safety profile for the Perioperative Enfortumab Vedotin, emphasizing its consistency with prior experiences involving the combination treatment.
Clinical Observations: Observations from clinical trials, specifically in the context of the EV-304 study, indicate that the safety profile aligns with previous findings, suggesting reliability in its application.
See More
Novavax Q4 Revenue Surges 67% Amid Strategic Shift
- Significant Revenue Growth: Novavax reported Q4 revenue of $147 million, a 67% year-over-year increase that surpassed market expectations of $90.26 million, indicating strong performance in the vaccine market, particularly driven by its collaboration with Sanofi.
- Strategic Shift: CEO John Jacobs stated that Novavax has transitioned from a singular focus on COVID vaccine commercialization to expanding its pipeline through partnerships and R&D, with expectations for global marketing of Nuvaxovid in the 2026-2027 season, enhancing its competitive position.
- Deepening Partnerships: The licensing agreement with Pfizer to utilize Matrix-M technology in two vaccine programs signifies progress in the company's diversification strategy, which is expected to help establish stable revenue streams in the future.
- Optimistic Market Sentiment: On Stocktwits, retail investor sentiment for Novavax is extremely bullish, with a 580% surge in message volume over 24 hours, reflecting strong confidence in the company's growth potential, as the stock has risen 67% year-to-date.
See More
FDA Launches Bonus Scheme for Early Drug Review Completion
- Incentive Program Launch: The FDA is set to implement a bonus scheme on April 1 aimed at rewarding scientific staff who complete drug reviews ahead of schedule, with bonuses potentially reaching a few thousand dollars per quarter, designed to enhance review efficiency.
- Targeted Departments: This initiative will apply to the FDA's Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), encouraging scientists and teams to expedite various sections of drug reviews, thereby improving overall review timelines.
- Talent Recruitment: The FDA is actively recruiting over 1,000 new scientists to accelerate drug review processes, a response to several high-profile departures in 2025, ensuring continuity and efficiency in review operations.
- Impact of Executive Departures: The FDA has faced significant leadership changes in 2025, including the resignations of Richard Pazdur from CDER and Peter Marks from CBER, prompting the agency to implement measures to stabilize its workforce and enhance review capabilities.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction Expectations: Rating changes by analysts typically attract market attention, as investors may adjust their positions based on these ratings, potentially impacting the price volatility of related stocks.
- Impact of Rating Changes: Upgrades can boost investor confidence and drive stock prices higher, while downgrades may lead to price declines, highlighting the significant role analysts play in the market.
- Access More Information: For a complete view of all analyst rating changes, including specific upgrades and downgrades, investors can visit our analyst ratings page to obtain the latest data and analysis.
See More
Pfizer's BRAFTOVI Receives Full FDA Approval
- FDA Full Approval: Pfizer's BRAFTOVI combination regimen has received full FDA approval for adult patients with metastatic colorectal cancer harboring the BRAF V600E mutation, based on significant survival improvements from the Phase 3 BREAKWATER trial, which is expected to enhance Pfizer's market presence in oncology.
- Positive Market Reaction: Following the FDA approval announcement, Pfizer's shares rose 0.02% to $27.14, reflecting a favorable market response, while the broader market also gained 0.53%, indicating a positive overall market environment.
- Technical Analysis Shows Short-term Pressure: Currently, Pfizer's stock is trading 3.1% below its 20-day and 5.4% below its 100-day simple moving averages, indicating some selling pressure in the short term, despite a 29% increase in share price over the past 12 months.
- Analyst Ratings Remain Neutral: The average price target for Pfizer's stock is $29.42, with analysts generally maintaining a Hold rating; Barclays has downgraded its rating to Underweight with a target of $25.00, reflecting a cautious outlook on Pfizer's future performance.
See More
ViiV Healthcare Unveils Phase 1 Data for VH184 and VH499 Long-Acting HIV Treatments
- VH184 Potential: VH184, the first third-generation integrase inhibitor, shows potential for twice-yearly dosing, with a single injection maintaining drug levels for up to six months, which could significantly reduce medication frequency for HIV patients and enhance their quality of life.
- Resistance Advantage: In vitro studies indicate that VH184 exhibits improved potency and resistance characteristics compared to bictegravir, retaining activity against various resistant HIV strains, highlighting its importance and competitive potential in future HIV treatments.
- VH499 Tolerability: VH499, an investigational capsid inhibitor, demonstrates good tolerability in clinical trials, supporting ultra-long-acting dosing every six months, potentially providing more treatment options for HIV patients and further driving ViiV's innovation in HIV care.
- R&D Commitment: ViiV Healthcare is committed to advancing innovative long-acting HIV therapies, with early data on VH184 and VH499 showcasing the company's efforts to reduce daily treatment needs, aligning with patient demands for more flexible treatment options and potentially transforming the future of HIV care.
See More
Astellas Reports Consistent Safety Profile for Perioperative Enfortumab Vedotin and Pembrolizumab in EV-304 Study
Safety Profile Overview: The document outlines the safety profile for the Perioperative Enfortumab Vedotin, emphasizing its consistency with prior experiences involving the combination treatment.
Clinical Observations: Observations from clinical trials, specifically in the context of the EV-304 study, indicate that the safety profile aligns with previous findings, suggesting reliability in its application.
See More
Novavax Q4 Revenue Surges 67% Amid Strategic Shift
- Significant Revenue Growth: Novavax reported Q4 revenue of $147 million, a 67% year-over-year increase that surpassed market expectations of $90.26 million, indicating strong performance in the vaccine market, particularly driven by its collaboration with Sanofi.
- Strategic Shift: CEO John Jacobs stated that Novavax has transitioned from a singular focus on COVID vaccine commercialization to expanding its pipeline through partnerships and R&D, with expectations for global marketing of Nuvaxovid in the 2026-2027 season, enhancing its competitive position.
- Deepening Partnerships: The licensing agreement with Pfizer to utilize Matrix-M technology in two vaccine programs signifies progress in the company's diversification strategy, which is expected to help establish stable revenue streams in the future.
- Optimistic Market Sentiment: On Stocktwits, retail investor sentiment for Novavax is extremely bullish, with a 580% surge in message volume over 24 hours, reflecting strong confidence in the company's growth potential, as the stock has risen 67% year-to-date.
See More
FDA Launches Bonus Scheme for Early Drug Review Completion
- Incentive Program Launch: The FDA is set to implement a bonus scheme on April 1 aimed at rewarding scientific staff who complete drug reviews ahead of schedule, with bonuses potentially reaching a few thousand dollars per quarter, designed to enhance review efficiency.
- Targeted Departments: This initiative will apply to the FDA's Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), encouraging scientists and teams to expedite various sections of drug reviews, thereby improving overall review timelines.
- Talent Recruitment: The FDA is actively recruiting over 1,000 new scientists to accelerate drug review processes, a response to several high-profile departures in 2025, ensuring continuity and efficiency in review operations.
- Impact of Executive Departures: The FDA has faced significant leadership changes in 2025, including the resignations of Richard Pazdur from CDER and Peter Marks from CBER, prompting the agency to implement measures to stabilize its workforce and enhance review capabilities.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction Expectations: Rating changes by analysts typically attract market attention, as investors may adjust their positions based on these ratings, potentially impacting the price volatility of related stocks.
- Impact of Rating Changes: Upgrades can boost investor confidence and drive stock prices higher, while downgrades may lead to price declines, highlighting the significant role analysts play in the market.
- Access More Information: For a complete view of all analyst rating changes, including specific upgrades and downgrades, investors can visit our analyst ratings page to obtain the latest data and analysis.
See More
